OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04757610 |
|
Recruitment Status :
Recruiting
First Posted : February 17, 2021
Last Update Posted : November 30, 2023
|
Sponsor:
Opthea Limited
Information provided by (Responsible Party):
Opthea Limited
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | December 2024 |